Cooperation and Expansion
International Development
With the Group's continuous businesses expansion and gradual R&D improvement, Sihuan Pharmaceutical gradually extends its reach internationally to explore further international cooperation.
Aesthetic medicine to promote product diversification
China's aesthetic medicine market is growing at a rate of more than 20% per year. In response to this trend, Sihuan has cooperated with Austrian pharmaceutical company Croma-Pharma GmbH to establish a joint venture. Its first product, Princess® VOLUME subcutaneous filler, was approved by the China Food and Drug Administration and is sold in mainland China. This product has been recognized by the market for its good effect in retaining youthful looks and its safety. At present, the Group has started clinical trials on other medical cosmetic products and is expected to further diversify its products in the near future.
Applying product approvals in both China and the U.S. to promote internationalization
Sihuan has carried out a strategic cooperation with Pharmadax and will gradually increase its investment in its FDA-certified factory in China—Guangzhou Foshan Pharmadax Pharmaceutical Co., Ltd. This cooperation with Pharmadax, an international drug R&D and production platform, will not only help Sihuan to obtain first-mover advantage in the domestic generic drug R&D and accelerate the launch of drugs in China, but will also lay the foundation for Sihuan products for approval application, registration and sales in the overseas market, thus further promote internationalization of the Group.
Innovative R&D lead to the future
In order to accelerate the progress of innovative drug pipeline and seize the opportunity to change the competitive landscape of the market, Sihuan has further sorted out, analyzed, assessed, prioritized and screened innovative novel drug projects. In addition to the current pipeline, Sihuan will focus on therapeutic areas with significant clinical needs, including oncology, tumor immunology, non-alcoholic steatohepatitis and diabetes, with a special focus on new targeted drugs and tumor immunotherapy. Sihuan will concentrate its resources on the R&D of eight major Class 1 new drugs, in which satisfactory progress has been achieved. Sihuan also has a number of generic drugs under R&D, some of which have already obtained clinical approvals. It is expected that Sihuan will launch a number of generic drugs to the market in the next 2-4 years.
Innovative academic promotion provides new drivers for development
With a multi-dimensional sales network nationwide involving more than 3,000 distributors and 600 sales & product managers, we segment the market and hold national professional academic promotion activities to fully realize potentials of our products. This unique marketing model ensures the market efficiency and provides new drivers for the development of Sihuan.